Checkmate Pharmaceuticals, Inc. Stock News

Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.

Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. The post Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 30

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to a

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Check

Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and I

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Associatio

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc.  (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary

Checkmate Pharmaceuticals Inc (CMPI) shares closed today at 1.6% above its 52 week low of $2.54, giving the company a market cap of $55M. The stock is currently down 10.1% year-to-date, down 83.0% over the past 12 months, and down 81.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 76.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 535.2% The company's stock price performance over the past 12 months lags the peer average by 169.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary t

Brokerages forecast that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) will report ($0.74) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Checkmate Pharmaceuticals earnings, with estimates ranging from ($0.74) to ($0.73). The business is expected to report its next earnings report on Monday, April 4th. According to Zacks, analysts []

Revolution Medicines (NASDAQ:RVMD) and Checkmate Pharmaceuticals (NASDAQ:CMPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Profitability This table compares Revolution Medicines and Checkmate Pharmaceuticals net margins, return on equity and []

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Stock analysts at Jefferies Financial Group dropped their FY2021 earnings estimates for shares of Checkmate Pharmaceuticals in a note issued to investors on Wednesday, November 24th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will post earnings per share of ($2.96) for the year, down from their []

Checkmate Pharmaceuticals (NASDAQ:CMPI) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Wednesday, Zacks.com reports. The firm presently has a $4.25 target price on the stock. Zacks Investment Researchs target price suggests a potential upside of 13.64% from the stocks previous close. According to []

Checkmate Pharmaceuticals (NASDAQ:CMPI) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, Checkmate Pharmaceuticals Inc. is a clinical stage biotechnology company. It is focused on developing proprietary technology to harness the power of the immune system to combat []

Brokerages expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to announce ($0.70) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Checkmate Pharmaceuticals earnings, with estimates ranging from ($0.73) to ($0.67). The firm is scheduled to announce its next earnings results on Monday, April 4th. According to Zacks, analysts expect that []